Group 6 Copy 53
-2
    Please wait...

    About This Project

    OncoSynergy, Inc.
    The Ebola outbreak in west Africa has been declared a global emergency by the WHO with over 1,000 victims and no approved therapies. OncoSynergy is developing a readily manufactured experimental cancer drug, OS2966, which coincidentally targets the receptor hijacked by ebola to infect cells. This project aims to demonstrate that OS2966 inhibits ebola infection of human cells thus providing the impetus for expediting OS2966 for treatment of ebola.
    Blast off!

    Browse Other Projects on Experiment

    Related Projects

    Dead wombats walking: Seasonal nutrition and mange in free-ranging bare-nosed wombats

    Bare-nosed wombats are under threat from sarcoptic mange caused by the sarcoptic mange mite, Sarcoptes scabieii...

    Investigating the presence of the amphibian chytrid fungus in a non-native species

    We're currently studying a population of the common midwife toad (Alytes obstetricans) in Cambridge, England...

    CRISPR Capsules: Packaging Cas9 with bacterial outer membrane vesicles

    NU iGEM is creating a delivery system for an innovative antibiotic method centered around CRISPR, a powerful...

    Backer Badge Funded

    A biology project funded by 47 people